+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Is APC resistance a risk factor for venous thromboembolism in patients over 70 years?

Is APC resistance a risk factor for venous thromboembolism in patients over 70 years?

Thrombosis and Haemostasis 88(4): 587-591

Activated protein C (APC) resistance is the most common risk factor for venous thromboembolism (VTE). Previous studies mostly analysed patients under 70 years and reported a four- to sevenfold increased risk. This case-control study included consecutive patients referred for a clinical suspicion VTE to our medical unit: 621 patients with a well-documented diagnosis (cases) and 406 patients for which the diagnosis was ruled out and who had no personal history of VTE (controls). APC resistance related to factor V Leiden was defined by either a positive DNA analysis or a positive STA(R) Staclot APC-R assay. Under 70 years, APC resistance was associated with a threefold increased risk of VTE (odds ratio 3.2, 95% CI, 1.7 to 6.0), whereas in patients over 70 years, it appeared to be no longer a strong risk factor (odds ratio 0.8, 95% CI, 0.4 to 1.7). Age appeared as an effect-measure modifier with a significant interaction (p = 0.005). Our data suggest that APC resistance is not a risk factor for VTE in elderly.

(PDF emailed within 1 workday: $29.90)

Accession: 010885931

Download citation: RISBibTeXText

PMID: 12362228

Related references

Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years. Thrombosis and Haemostasis 106(5): 901-907, 2012

Factor XII (Hageman factor) deficiency: a risk factor for development of thromboembolism. Incidence of factor XII deficiency in patients after recurrent venous or arterial thromboembolism and myocardial infarction. Wiener Medizinische Wochenschrift 143(2): 43-50, 1993

Risk factor profile and outcomes of patients treated for venous thromboembolism with low molecular weight heparin Findings from the veenous thromboembolism Registry. Blood 102(11): 128b, November 16, 2003

The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thrombosis and Haemostasis 83(2): 204-208, 2000

Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. British Journal of Haematology 133(1): 68-77, 2006

The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Archives of Internal Medicine 162(20): 2357-2360, 2002

Family history of venous thromboembolism is a risk factor for venous thromboembolism in combined oral contraceptive users: a nationwide case-control study. Thrombosis Journal 13(): 34-34, 2015

Inherited risk factors in low-risk venous thromboembolism in patients under 45 years. Interactive Cardiovascular and Thoracic Surgery 20(1): 21-23, 2015

Patients with venous thromboembolism have a lower APC response than controls. Should this be regarded as a continuous risk factor for venous thrombosis?. Haematologica 84(5): 470-472, 1999

Activated protein C resistance: the most common risk factor for venous thromboembolism. Journal of the American Board of Family Practice 13(2): 111-115, 2000

Usefulness of antithrombin deficiency phenotypes for risk assessment of venous thromboembolism: type I deficiency as a strong risk factor for venous thromboembolism. International Journal of Hematology 92(3): 468-473, 2011

Impact of chemotherapy on venous thromboembolism: comment to: regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica 98(12): E153-E154, 2014

Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation. Blood Coagulation & Fibrinolysis 10(7): 409-416, 2000

Questionnaire for assessing the risk of venous thromboembolism in hospitalized surgical and non-surgical patients in the 4th Hungarian antithrombotic guideline entitled "Risk reduction and treatment of venous thromboembolism". Orvosi Hetilap 151(34): 1365-1374, 2010

Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 126(4): 448-454, 2012